Research this month includes updates on emerging treatments, screening, and prevention.
In gastric cancer treatment news, Athenex, Inc. has released encouraging results in their recently completed Phase 1 clinical trial for Oraxol (oral paclitaxel) plus CYRAMZA (ramucirumab) in gastric cancer patients who had failed previous chemotherapy treatments. Oraxol is an oral formulation of paclitaxel, a commonly used chemotherapy, combined with HM30181A (a novel P-gp inhibitor).
Read more here.
There is also news about screening. Although it's a long way from being a marketable device, researchers at Johns Hopkins Kimmel Cancer Center have developed a blood test (CancerSEEK) that screens and identifies the location of certain cancer types, including gastric cancer.
Find out more here.
Another study in the
World Journal of Surgery
has found a combination of CRP/Alb ratio and NLR can be an independent prognostic indicator for gastric cancer.
And on the risk factor side, a prospective study in
quantifies the cancer risk associated with each gastritis stage. Another study using genomic technologies and published in
investigates the effects of having Helicobacter pylori infections and intestinal metaplasia on gastric cancer occurrence and progression.